An industrial distributor gives its account managers AI that brings together what the company knows about each customer: purchasing patterns, service history, and what engineering learned on past jobs. They can now identify unmet needs and opportunities they previously couldn't see, and begin proposing tailored solutions instead of simply taking orders.
That depends on pricing.
Proposals increasingly combine products and technical services that don't fit standard pricing. The existing process for approving nonstandard deals can't keep up. Finance and pricing must establish rules that let account managers price most proposals themselves, while protecting margins and escalating unusual commitments.
Which depends on operations.
Tailored proposals create demands for sourcing, technical support and delivery that standard orders don't. Operations must assess cost, capacity and lead times before the promise is made, not after. That changes how sales and operations work together.
Which depends on how people are measured.
Account managers are rewarded for sales volume and operations for efficiency. Both incentives now work against the more complex, potentially higher-margin solutions the company wants to sell. Performance measures and compensation must reflect the new priorities.
The tool worked on day one. The full value arrived only after pricing authority, operational planning and incentives had changed. Each function could see its own link, but nobody was responsible for seeing the entire chain.
An equipment manufacturer gives its field technicians AI that draws on years of service records and knowledge captured from its best technicians: fault patterns, fixes that worked, the quirks of each machine generation. A two-year technician can now resolve problems that previously required one of five senior specialists.
That depends on the senior technicians.
Their value was being the people who could solve the hardest problems. Now they also have to keep the knowledge current, validate new solutions and handle problems nobody has seen before. Their responsibilities and schedules must change to support this, or the knowledge gradually becomes outdated.
Which depends on dispatch and parts.
More jobs can be assigned to less experienced technicians, but a correct diagnosis only delivers a first-visit fix if the right part is available. Dispatch, scheduling and parts planning must adapt to new patterns of technician capability and repair demand.
Which depends on what the company sells.
With faster, more reliable repairs, the company sees an opportunity to sell equipment uptime instead of billing repair hours. But guaranteeing uptime also requires dependable maintenance and parts availability. Sales, service and finance must rethink the contracts, pricing and financial risks.
The tool worked on day one. The full value arrived only after technician roles, dispatch, parts planning and the service business model had changed. Each function could see its own link, but nobody was responsible for seeing the entire chain.
A medical device company gives its development engineers AI that draws on years of regulatory, quality, clinical and manufacturing records: what regulators questioned, which design choices led to complaints, what the plant struggled to build. Engineers can now evaluate design alternatives against that experience before committing, and explore options that previously required too much time or carried too much uncertainty.
That depends on regulatory and quality.
They already participate in development, but through scheduled reviews and defined checkpoints. Now engineers can explore and revise options much faster. Questions about safety, compliance and design implications arise continuously. Regulatory and quality must become more involved in day-to-day decisions without compromising required controls.
Which depends on the stage gates.
The development process was built around a slower pace of engineering decisions and formal reviews. When alternatives can be evaluated much faster, the existing review schedule becomes a bottleneck. How decisions are documented, reviewed and approved has to change, even though the regulatory requirements remain.
Which depends on commitments outside engineering.
Manufacturing and suppliers must assess feasibility while designs are still evolving. Clinical teams must evaluate evidence requirements for more alternatives. Purchasing and finance must support these activities earlier, before the usual spending and approval milestones.
The tool worked on day one. The full value arrived only after the roles of regulatory and quality, the development process and the timing of cross-functional commitments had changed. Each function could see its own link, but nobody was responsible for seeing the entire chain.